By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Novo Nordisk A/S 

Novo Allé

Bagsvaerd    2880  Denmark
Phone: 45-4444-8888 Fax: 45-4449-0555


Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.




Founders: August Krogh and Marie Krogh

CEO: Lars Rebien Sørensen

CFO: Jesper Brandgaard

CSO (Scientific): Mads Krosgsgaard Themsen


Please click here for Novo Nordisk job opportunities.


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: Novo Nordisk A/S
Employees: 13395
Symbol: NVO

Big Pharma


CelTor Biosystems, Inc.  Research collaboration

Aradigm Corporation  Commercial agreement to develop AERx technology for the delivery of insulin, insulin analogues and other glucose-lowering agents for diabetes management.

Maxygen, Inc. 

Intergen Company 

Company News
Korean Firms Acquire Novo Nordisk A/S (NVO)’s U.S. HQ for $305 Million 8/19/2016 6:29:01 AM
Novo Nordisk A/S (NVO) Plummets Amid Pricing Challenges in U.S. Market 8/5/2016 6:20:23 AM
Novo Nordisk A/S (NVO)'s Blockbuster Diabetes Med Victoza Does Not Help Severe Heart Failure 8/4/2016 7:25:22 AM
Novo Nordisk A/S (NVO) Announces New Data On Psychosocial Impact Of People Living With Hemophilia B 7/26/2016 8:05:01 AM
Lyfebulb Partners With Novo Nordisk A/S (NVO) To Support Patient-Driven Innovations For People With Diabetes 7/19/2016 9:26:03 AM
Novo Nordisk A/S (NVO) To Present 28 Abstracts At The World Federation Of Hemophilia World Congress In Orlando 7/12/2016 8:17:24 AM
Unique New Book Series From Novo Nordisk A/S (NVO) And JDRF Uses Customized Information By Age To Educate Children And Young Adults With Type 1 Diabetes 7/6/2016 8:32:29 AM
Backed by Novartis AG (NVS) and Novo Nordisk A/S (NVO), UK Biotech F2G Bags $60 Million 6/20/2016 5:53:12 AM
Novo Nordisk A/S (NVO) Release: Victoza (Liraglutide) Significantly Reduced The Risk Of Major Cardiovascular Events And Death In Adults With Type 2 Diabetes In The LEADER Trial 6/14/2016 1:23:27 PM
Novo Nordisk A/S (NVO) Release: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In Hba1c In Type 1 Diabetes And A Comparable Hba1c Reduction In Type 2 Diabetes Versus Novolog® (Insulin Aspart [rDNA Origin] Injection) 6/14/2016 11:59:02 AM